HSD8 Assessing the Environmental Value of Semaglutide: Reduction in GHG Emissions Resulting From the Treatment of Obese Individuals With Type 2 Diabetes
Emily Archer Goode, Amy Swanston, Rebecca Mackley, Antony Wright, Lindsay Nicholson
Value in Health, Volume 28, Issue 12, Supplement 1S374, December 2025, doi: 10.1016/j.jval.2025.09.1669
Abstract
In England, 64.5% of adults are overweight or obese. Higher body mass index (BMI) is associated with greater healthcare resource use (HCRU), partly due to co-morbidities such as type 2 diabetes (T2D). Semaglutide treatments (glucagon-like peptide-1 [GLP-1] receptor agonists) reduce BMI and improve cardiometabolic risk factors. Healthcare is a major contributor to greenhouse gas emissions (GHG). This study aimed to evaluate the environmental impact of semaglutide treatment by estimating the GHG emissions, measured as carbon dioxide equivalents (CO2e), associated with HCRU in obese patients with T2D, with and without semaglutide treatment.